克罗米酚对男性较低促性腺素性功能减退症有效

西雅图（汤森社肥胖症版）1月底四日报导：据发表在12月底选集的《未婚与不育》杂志的一项报告指出克罗米衍生物对外低促特质腺素顺利进行特质减退的异特质恋患儿有利。来自伯明翰阿拉巴马大学的该报告的第一创作者Scott J. Whitten哈佛大学在接纳汤森汤森社采访时说：“功能障碍或获得特质HH患儿在接纳触犯特质更大和更为较贵的疗程（例如注射促特质腺激素类）前顺利进行4个月底的克罗米衍生物试验特质疗程是有利的。”Whitten哈佛大学和同事科学研究了克罗米衍生物对10名HH异特质恋患儿（HH是造成了异特质恋不育的少见因素）是否有效。报告称克罗米衍生物疗程1年后，4名卡尔曼(其族)综合征患儿中只有一名患儿的乳腺沸点增加而全垂体功能减退症患儿的乳腺忽视症状均没得到改善。相反，该报告指出3名幼小发病的功能障碍HH异特质恋患儿经过3个月底克罗米衍生物的疗程乳腺沸点有了明显增加。目前为止该组患儿已为两名回复了未婚能力。Whitten哈佛大学说：“除非对克罗米衍生物疗程没中间体，我们不会因为副作用停止对患儿使用该药物。”之后创作者总结说：“因为条件极小，对HH患儿促特质腺激素抑制剂和克罗米衍生物的随机科学研究较难顺利进行，然而来进行多系列的严格选择标准对患儿顺利进行分级可能会协助全面验证克罗米衍生物回复异特质恋低未婚能力的有效特质。 Male Hypogonadotropic Hypogonadism May Respond to Clomiphene CitrateBy Will Boggs, MDNEW YORK (Reuters Health) Jan 04 - Some men with hypogonadotropic hypogonadism (HH) benefit from treatment with clomiphene citrate, according to a report in the December issue of Fertility and Sterility.Patients with idiopathic or acquired HH "may benefit from a 4-month trial (of clomiphene citrate) before proceeding with more invasive and expensive therapies, such as injectable gonadotropins," lead author Dr. Scott J. Whitten, from University of Alabama at Birmingham, told Reuters Health.Dr. Whitten and colleagues investigated whether 10 men with HH, a rare cause of male infertility, might respond to treatment with clomiphene citrate.Only one of four patients with Kallmann's syndrome experienced an improvement in sperm concentration after 1 year of therapy with clomiphene citrate, the authors report, and no patient with panhypopituitarism experienced a reversal of azoospermia with clomiphene citrate treatment.In contrast, all three men with -onset idiopathic HH experienced significant increases in sperm concentrations and testosterone levels after 3 months of therapy with clomiphene citrate, the report indicates. Two pregnancies he been achieved in this subgroup so far."We did not he any of our patients discontinue the clomiphene because of side effects, only if there was lack of response," Dr. Whitten said."Because this is such a rare condition, additional randomized studies comparing gonadotropins with clomiphene in this subtype of HH patients would be difficult to perform," the authors conclude. "However, larger series using strict inclusion criteria for stratifying patients may be helpful to further examine the success of clomiphene treatment in restoration of this form of male subfertility."Fertil Steril 2006;86:1664-1668.

主笔：蓝色想像

主笔： 张靖